[
    {
        "molecule_name": "immunoglobulin",
        "protein_target_name": "FcγRIIb",
        "binding_metric": "Kd",
        "value": "<100",
        "unit": "nM",
        "raw_mentions": "In one embodiment, the immunoglobulin binds with FcγRIIb, wherein the affinity of said binding has a Kd less than about 100 nM, e.g., less than or equal to about 95 nM, less than or equal to about 90 nM, less than or equal to about 85 nM, less than or equal to about 80 nM, less than or equal to about 75 nM, less than or equal to about 74 nM.\nIn another embodiment, the immunoglobulin is a bispecific antibody comprising a first Fv region and a second Fv region, wherein said first Fv region binds the target antigen, and said second Fv region binds FcγRIIb with a Kd of less than about 100 nM.\nIn another embodiment, the immunoglobulin is an Fc fusion comprising an Fc region, wherein said Fc region binds FcγRIIb with a Kd of less than about 100 nM.\nThe compositions disclosed herein include immunoglobulins that bind FcγRIIb+ cells and coengage a target antigen on the cell's surface and an FcγRIIb on cell's surface, wherein the affinity of said binding has a Kd less than about 100 nM, e.g., less than or equal to about 95 nM, less than or equal to about 90 nM, less than or equal to about 85 nM, less than or equal to about 80 nM, less than or equal to about 75 nM, less than or equal to about 74 nM."
    },
    {
        "molecule_name": "bispecific antibody",
        "protein_target_name": "FcγRIIb",
        "binding_metric": "Kd",
        "value": "<100",
        "unit": "nM",
        "raw_mentions": "In one embodiment, the immunoglobulin binds with FcγRIIb, wherein the affinity of said binding has a Kd less than about 100 nM, e.g., less than or equal to about 95 nM, less than or equal to about 90 nM, less than or equal to about 85 nM, less than or equal to about 80 nM, less than or equal to about 75 nM, less than or equal to about 74 nM.\nIn another embodiment, the immunoglobulin is a bispecific antibody comprising a first Fv region and a second Fv region, wherein said first Fv region binds the target antigen, and said second Fv region binds FcγRIIb with a Kd of less than about 100 nM.\nIn another embodiment, the immunoglobulin is an Fc fusion comprising an Fc region, wherein said Fc region binds FcγRIIb with a Kd of less than about 100 nM.\nThe compositions disclosed herein include immunoglobulins that bind FcγRIIb+ cells and coengage a target antigen on the cell's surface and an FcγRIIb on cell's surface, wherein the affinity of said binding has a Kd less than about 100 nM, e.g., less than or equal to about 95 nM, less than or equal to about 90 nM, less than or equal to about 85 nM, less than or equal to about 80 nM, less than or equal to about 75 nM, less than or equal to about 74 nM."
    },
    {
        "molecule_name": "Fc fusion",
        "protein_target_name": "FcγRIIb",
        "binding_metric": "Kd",
        "value": "<100",
        "unit": "nM",
        "raw_mentions": "In one embodiment, the immunoglobulin binds with FcγRIIb, wherein the affinity of said binding has a Kd less than about 100 nM, e.g., less than or equal to about 95 nM, less than or equal to about 90 nM, less than or equal to about 85 nM, less than or equal to about 80 nM, less than or equal to about 75 nM, less than or equal to about 74 nM.\nIn another embodiment, the immunoglobulin is a bispecific antibody comprising a first Fv region and a second Fv region, wherein said first Fv region binds the target antigen, and said second Fv region binds FcγRIIb with a Kd of less than about 100 nM.\nIn another embodiment, the immunoglobulin is an Fc fusion comprising an Fc region, wherein said Fc region binds FcγRIIb with a Kd of less than about 100 nM.\nThe compositions disclosed herein include immunoglobulins that bind FcγRIIb+ cells and coengage a target antigen on the cell's surface and an FcγRIIb on cell's surface, wherein the affinity of said binding has a Kd less than about 100 nM, e.g., less than or equal to about 95 nM, less than or equal to about 90 nM, less than or equal to about 85 nM, less than or equal to about 80 nM, less than or equal to about 75 nM, less than or equal to about 74 nM."
    },
    {
        "molecule_name": "immunoglobulins",
        "protein_target_name": "FcγRIIb",
        "binding_metric": "Kd",
        "value": "<100",
        "unit": "nM",
        "raw_mentions": "In one embodiment, the immunoglobulin binds with FcγRIIb, wherein the affinity of said binding has a Kd less than about 100 nM, e.g., less than or equal to about 95 nM, less than or equal to about 90 nM, less than or equal to about 85 nM, less than or equal to about 80 nM, less than or equal to about 75 nM, less than or equal to about 74 nM.\nIn another embodiment, the immunoglobulin is a bispecific antibody comprising a first Fv region and a second Fv region, wherein said first Fv region binds the target antigen, and said second Fv region binds FcγRIIb with a Kd of less than about 100 nM.\nIn another embodiment, the immunoglobulin is an Fc fusion comprising an Fc region, wherein said Fc region binds FcγRIIb with a Kd of less than about 100 nM.\nThe compositions disclosed herein include immunoglobulins that bind FcγRIIb+ cells and coengage a target antigen on the cell's surface and an FcγRIIb on cell's surface, wherein the affinity of said binding has a Kd less than about 100 nM, e.g., less than or equal to about 95 nM, less than or equal to about 90 nM, less than or equal to about 85 nM, less than or equal to about 80 nM, less than or equal to about 75 nM, less than or equal to about 74 nM."
    },
    {
        "molecule_name": "immunoglobulin",
        "protein_target_name": "FcγRIIb",
        "binding_metric": "Kd",
        "value": "<100",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* In one embodiment, the antigen screening methods disclosed herein comprise the step of binding a cell that expresses the target antigen and FcγRIIb with an immunoglobulin that binds with enhanced affinity, e.g., the Kd of the immunoglobulin may be less than about 100 nM to at least FcγRIIb."
    },
    {
        "molecule_name": "IgG1",
        "protein_target_name": "FcγRIIb",
        "binding_metric": "Kd",
        "value": "1500",
        "unit": "nM",
        "raw_mentions": "WT (native) IgG1 binds FcγRIIb with an affinity of about 1.5 μM, or about 1500 nM.\nSome Fc variants described herein bind FcγRIIb with an affinity about 10-fold greater to WT IgG1.\nAs disclosed herein, greater or enhanced affinity means having a K<sub>D </sub>lower than about 100 nM, for example between about 10 nM-about 100 nM, between about 1-about 100 nM, or less than about 1 nM."
    },
    {
        "molecule_name": "IgG1",
        "protein_target_name": "FcγRIIb",
        "binding_metric": "Kd",
        "value": "1.5",
        "unit": "μM",
        "raw_mentions": "WT (native) IgG1 binds FcγRIIb with an affinity of about 1.5 μM, or about 1500 nM.\nSome Fc variants described herein bind FcγRIIb with an affinity about 10-fold greater to WT IgG1.\nAs disclosed herein, greater or enhanced affinity means having a K<sub>D </sub>lower than about 100 nM, for example between about 10 nM-about 100 nM, between about 1-about 100 nM, or less than about 1 nM."
    },
    {
        "molecule_name": "WT IgG1 Fc",
        "protein_target_name": "FcγRIIb",
        "binding_metric": "Kd",
        "value": "1467",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n* Whereas WT IgG1 Fc binds with FcγRIIb with μM affinity (Kd=1467 nM in FIG. 7), a large number of variants have been engineered that bind more tightly.\n* The variant with the highest affinity for FcγRIIb, S267E/L328F, shows over 2 orders of magnitude improvement in affinity to FcγRIIb, and significantly reduced affinity to the activating receptors, including FcγRIIIa, FcγRI, and H131 FcγRIIa."
    },
    {
        "molecule_name": "S267E/L328F variant of IgG1",
        "protein_target_name": "FcγRIIb",
        "binding_metric": "EC50",
        "value": "approximately 320-fold relative to WT IgG1",
        "unit": null,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nThe cell-surface binding confirmed that the S267E/L328F variant of those tested has the highest affinity for FcγRIIb, with an EC50 approximately 320-fold relative to WT IgG1.\nhalf-maximal binding (EC50) values were determined by sigmoidal dose response modeling.\nThe EC50 values of the variants tested showed a similar rank order as the Biacore results."
    }
]